This study focuses on patients with depression, including both unipolar and bipolar types, who are receiving electroconvulsive therapy (ECT) and are currently taking medications called benzodiazepines. The research examines the use of a medication called flumazenil, which is designed to reverse the effects of benzodiazepines during ECT treatment.
The purpose of this research is to determine if using flumazenil can reduce memory and thinking-related side effects that can occur with ECT treatment, while still maintaining its effectiveness in treating depression. The study will also look at how this approach affects the brain’s memory networks. During the study, participants will receive either flumazenil or a placebo through an injection before their ECT sessions.
Throughout the study period, which lasts up to three months, various aspects will be monitored, including memory function, thinking abilities, and how well the treatment works for depression symptoms. The research will also assess how quickly patients recover after each treatment session and their overall satisfaction with the procedure.
Denmark 
